《新股消息》中國石墨(02237.HK)公開發售超購25.5倍及下限定價0.325元 一手中籤率30%
中國石墨(02237.HK)公布招股結果,每股發售價定為0.325元,為招股價範圍(招股價介乎0.325元至0.375元)下限,香港公開發售部分錄得約25.51倍超額認購,經重新分配後,在港公開發售股數增至總發售的30%。該股將於下周一(18日)掛牌。每手10,000股計,中籤率30.01%。獨家保薦人為力高企業融資。
公司料上市集資淨額約8,380萬元,公司擬將所得款項淨額約32.4 %用作土地收購成本;約31.6%用作建設成本;及約36%用於購買和安裝機械及設備。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.